Alzheimer's Society comment on new research suggesting tarenflurbil may be effective in halting symptoms of Alzheimer's disease, from the Lancet Neurology
Published 2 May 2008
This exciting clinical trial suggests a modification of a safe and readily available anti-inflammatory drug has a positive impact on memory and function for people with mild Alzheimer's disease.
A drug that slows the effects of this devastating disease would provide hope to thousands who are diagnosed each year. Two more clinical trials of this drug are currently underway and we eagerly look forward to the results of these studies next year.
Prof Clive Ballard
Director of Research
Alzheimer's Society
Reference
Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial, http://neurology.thelancet.com/, (Gordon K Wilcock, Sandra E Black, Suzanne B Hendrix, Kenton H Zavitz, Edward A Swabb, Mark A Laughlin, on behalf of the Tarenflurbil Phase II Study investigators)
